Noxilizer and Sterigenics International have announced the signing of a global agreement that will make Sterigenics the exclusive worldwide provider of nitrogen dioxide (NO2) contract sterilization services, as well as feasibility and research studies, to the pharmaceutical, biotech and medical device manufacturing industries.
NO2-based sterilization was first commercialized by Noxilizer in 2012. Customers prefer nitrogen dioxide sterilization for its key advantages: ultra-low temperature (10°-30°C), minimal pressure requirements, no cytotoxic residuals, and fast cycle times (2-4 hours, including aeration). NO2 sterilization opens new avenues for medical device innovation and has been shown to be particularly effective in the sterilization of prefilled syringes, drug-device combination products, and custom implants.
President and CEO of Noxilizer Lawrence Bruder says: “We are very excited about our partnership with Sterigenics, as together we can rapidly expand NO2 sterilization capability for our customers.
“Noxilizer’s customers will now have large-scale facilities to meet their needs for contract services, redundancy and increasing volumes.”
President of Sterigenics Philip Macnabb said: “Sterigenics is committed to providing our customers with efficient, state-of-the-art sterilization services using the processes best suited to their specific products.
“We regularly monitor new technologies and are excited to be able to add NO2 processing to our suite of offerings.”
Noxilizer expects to have the first NO2 sterilization systems in place and operational in select Sterigenics’ facilities in the United States and Europe by the end of the year with additional installations to follow. As part of the agreement, Sterigenics will also offer nitrogen dioxide sterilization consulting services to its customers.
Customers will also be able to benefit from the integrated testing services available through Sterigenics International’s Nelson Laboratories business.
President of Nelson Labs Jeff Nelson said: “This unique combination of cutting edge sterilization technologies, expert consulting support, and full-service testing services will provide customers with unrivalled support in getting products to market quickly and reliably,”
“Sterigenics has set a high standard for matching the needs of its customers with the best available sterilization technologies,” Lawrence Bruder concluded. “Noxilizer shares this commitment to excellence and we look forward to working with the Sterigenics International team as they continue to reshape the market.”
Noxilizer provides an ultra-low temperature nitrogen dioxide process that offers many benefits over traditional sterilization and biodecontamination methods.
Noxilizer sells sterilization and biodecontamination equipment to pharmaceutical, biotech and medical device manufacturers. Noxilizer’s expert microbiology and material compatibility team are ready to partner to solve sterilization challenges through every phase of the process. Noxilizer has offices in the US and Japan.